[Treatment of essential hypertension--its recent progress].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002395:Catecholamines / Q000096:biosynthesis; D004232:Diuretics / Q000627:therapeutic use; D004299:Dopamine beta-Hydroxylase / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D013148:Spironolactone / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002395:Catecholamines; D004232:Diuretics; D014665:Vasodilator Agents; D013148:Spironolactone; D004299:Dopamine beta-Hydroxylase